Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | RARB | P10826 | 3/20 | 0.60 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12562032 | 1.00 | CYP2D6 (0.61) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL17951695 | 0.98 | RARB (0.63) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL10128654 | 0.98 | RARB (0.63) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL10128616 | 0.98 | RARB (0.63) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL8239315 | 0.98 | RARB (0.63) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL24727755 | 0.98 | RARB (0.63) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL13402142 | 0.96 | RARB (0.61) | CYP2D6CYP3A4RARBNR5A1LTA4H | |
| SCHEMBL2489516 | 0.96 | CYP2D6 (0.66) | CYP2D6CYP3A4RARBLTA4HCYP19A1 | |
| SCHEMBL6377570 | 0.94 | NR5A1 (0.64) | CYP2D6CYP3A4NR5A1LTA4HDRD2 | |
| SCHEMBL21167283 | 0.92 | NR5A1 (0.68) | RARBNR5A1LTA4HDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524980-B2 | Synthesis of echinocandin antifungal agent | CIDARA THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-10780144-B2 | Methods for preventing and treating pneumocystis infections | CIDARA THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20170327540-A1 | METHOD FOR ACYLATING A CYCLIC PEPTIDE | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2017-11-16 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-8022033-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022033-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100273977-A1 | PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES | BOFFELLI PHILIPPE | 2010-10-28 | — | — | US | disclosed |
| US-7709444-B2 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709444-B2 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090258820-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ELI LILLY AND COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258820-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ELI LILLY AND COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-7550428-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070105760-A1 | Process for the preparation of echinocandin derivatives | BOFFELLI PHILIPPE | 2007-05-10 | — | — | US | disclosed |
| US-20050032679-A1 | Process for the preparation of echinocandin derivatives | AVENTIS PHARMA S.A. (FR) | 2005-02-10 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105760-A1 | Process for the preparation of echinocandin derivatives | EML4, XPO1, CYP51A1 | CYP2D6 20/4885CYP3A4 36/4885RARB 2698/4885 |
| US-20090258820-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ERG28, TREH, MAN2A1 | CYP2D6 1649/4885CYP3A4 636/4885RARB 4638/4885 |
| US-20050032679-A1 | Process for the preparation of echinocandin derivatives | EPOR, EML4, XPO1 | CYP2D6 30/4885CYP3A4 40/4885RARB 1777/4885 |
| US-20170327540-A1 | METHOD FOR ACYLATING A CYCLIC PEPTIDE | VIP, NGLY1, PTMS | CYP2D6 4075/4885CYP3A4 3435/4885RARB 4728/4885 |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | CYP2D6 3738/4885CYP3A4 2774/4885RARB 2983/4885 |
| US-11524980-B2 | Synthesis of echinocandin antifungal agent | ERG28, DHPS, FDPS | CYP2D6 458/4885CYP3A4 441/4885RARB 4716/4885 |
| US-20100273977-A1 | PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES | EML4, XPO1, CYP51A1 | CYP2D6 20/4885CYP3A4 36/4885RARB 2698/4885 |
| US-10780144-B2 | Methods for preventing and treating pneumocystis infections | TPMT, TYMP, TST | CYP2D6 1068/4885CYP3A4 1564/4885RARB 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.